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Abstract 
The burden of managing chronic oedema can be considerable to the National Health Service 
(NHS). Developing innovative solutions to the care and management of patients with chronic 
oedema has the potential to deliver prudent, cost-effective and high quality care within NHS 
Wales.  
The aim of this economic analysis was to estimate the economic impact of the On the Ground 
Education Programme (OGEP) within one local University Health Board (UHB) in Wales. A 
questionnaire collected health care service use data prior to receiving the OGEP (baseline) 
and at 3 months follow-up from 97 patients. In addition, we analysed a patient reported 
health outcome using the EQ-5D 5L which was completed by patients at the same two 
assessment points. The total cost of managing chronic oedema in the 97 patients recruited 
was £563,729 (mean patient cost £5,812 SD (£5,870) at baseline and £445,098 (including the 
addition of intervention costs) (mean patient cost £4,589 (SD £5,465) at 3 months follow up. 
Improvements in the EQ-5D 5L score increasing from 0.40 (SD 0.25) at baseline to 0.54 (SD 
0.23) at 3 months follow-up. Our findings show health care resource use and costs decreased, 
whilst HRQOL scores increased.  
 
Contribution of the paper 
Key messages of the paper: 
 Health care resource use and costs decreased 
 HRQOL scores increased 
What the paper adds to the current literature: 
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 Evidence for the beneficial effects of delivering best standard of care practice 
What new knowledge is added by this study: 
 Promotion of proactive care proves beneficial over reactive care 
 Patient HRQOL gains 
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Introduction and background 
 
Chronic oedema is a debilitating, enduring condition connected with several chronic 
conditions, primary and secondary lymphoedema, obesity and immobility, with prevalence 
greatest within the older population (Todd 2013). It is characterised by atypical swelling 
lasting for more than three months. Those affected may experience skin changes, recurrent 
cellulitis, superficial ulceration, exudate, lymphoedema and enduring pain, reduced mobility 
and discomfort (Todd 2013). Evidence suggests that the impact of chronic oedema/leg ulcers 
on an individual’s health, well-being, sense of self and quality of life may be profound and 
extends to all those who are important to the individual.  
As a chronic debilitating condition, chronic oedema can have significant impact on health 
outcomes and result in a significant burden to the UK National Health Service (NHS).   
Ineffective prevention and management alongside inappropriate prescribing of dressing and 
garments have been identified as significant issues and with appropriate management based 
on clinically and cost-effective technologies, the NHS could make substantial cost savings and 
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enhance patient outcomes, including  health–related quality of life (HRQOL) (Ashby et al, 
2014). 
 
Lymphoedema Network Wales have been developing innovative methods to support the 
management of chronic oedema within the community setting. One innovation has been the 
development of the OGEP which is a community-based education model involving the use of 
video prescription film applications as well as an educator training programme to support 
community health professionals and patients in the management and care of chronic 
oedema. The management includes daily activity and exercises, compression therapy/ multi 
layer lymphoedema bandaging, skin care and general public health promotion. Whilst the 
OGEP intervention  requires additional investment in terms of resources to deliver, it could 
potentially result in more efficient use of health care resources including correct prescribing 
of dressing and garments from the All-Wales Lymphoedema Compression Garment Formulary 
(All-Wales Lymphoedema Compression Garment Formulary  2017), alongside improving 
outcomes and experiences for people living with chronic oedema. 
Aim and objectives 
 
The aim of this economic analysis, based on the pilot evaluation of the OGEP was to estimate 
the economic impact of the OGEP within one local University Health Board (UHB) within 
Wales. Specific objectives were to:  
 Assess the health care resource use and related costs associated with the delivery of 
the OGEP compared to ‘no OGEP’ i.e. the status quo.  
 Estimate changes in the profile of health services delivered to patients as a result of 
the OGEP model. 
 Provide a description of preference – based patient health outcome before and after 
receiving the OGEP.   
The perspective taken was NHS/Personal Social Service (PSS) i.e. we considered direct health 
care costs across primary and secondary health care and direct costs associated with paid 
carers/social care (PSS).  
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Methods  
 
The pilot evaluation design was an observational ‘before-after design’ with baseline 
assessment of resource use, costs and outcomes done at the time patients were identified 
and/or began to receive the OGEP and at 3 months afterwards.  All patients were selected 
and recruited by the OGEP team, based on their eligibility to receive the OGEP during the    
pilot evaluation period. The estimated sample size within the evaluation period was 100 
patients. As this was in effect a single arm study i.e. there was no comparator; the economic 
evaluation cannot fulfil the essential characteristic of a full economic evaluation in order to 
address questions of cost-effectiveness. Ethical approval was granted from Swansea 
University for data analysis on anonymised information.  The UHB Research and Development 
department granted service evaluation approval. 
Data collection measures 
Data collection was administered by the OGEP team using an appropriate resource utilisation 
questionnaire (RUQ) to obtain health care resource use over a 3 months period.  
The EQ-5D 5L (EUROQOL, 2017) was administered by the OGEP team at baseline and 3 
months. The visual analogue scale (VAS) and descriptive system scores were also recorded by 
the OGEP team.  
Resource use associated with the management and care of chronic oedema was summarized 
into relevant categories (e.g. primary care, secondary care, medication and dressing costs) 
and valued in £ sterling using a price year of 2016. The costs were determined from national 
published sources of unit costs [including All Wales Lymphoedema Compression Garment and 
Wound Care 2017), British National Formulary (BNF 2017), NHS reference costs (NHS 2016) 
and Personal and Social Services Research Unit (PSSRU 2016).  Where costs were unavailable 
and/or the client wishes to use local costs (e.g. from local financial records or NHS Wales 
formulary). The currency year used was 2015/2016. If relevant costs were not available for 
these years, an inflation calculator (Bank of England) was used to convert costs to the price 
year(s). 
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Results 
One hundred patients were recruited into the pilot evaluation by the OGEP team over the 
evaluation time period.  Three participants died during the study prior to the 3 month follow-
up assessment and were excluded from the analysis. The final sample included in the analysis 
was 97 participants. 64.9% of participants were female and 68% were from the Vale of 
Glamorgan. 32% were from the Cardiff North & West area with a mix of participants from the 
cluster of Barry 1 & 2, Cowbridge, Penarth, Rhiwbina and Whitchurch. 
Intervention costs 
Table 1 presents the overall costs of the OGEP intervention. This was estimated at £35,812 
(£358.12 per patient) over the pilot evaluation period. The agreed intervention costs covered 
the staff resources associated with the delivery of the OGEP model of care.  
Table 1: Intervention costs of the OGEP 
Costs Item 
Unit 
cost 
per 
hr. 
Resource 
Usage 
Cost 
Unit cost 
source/Description 
Comments/Assumptions 
made 
Training Cost 
Nurse/ 
Physiotherapist 
(Band 8a) 
£62 14 Hours £868 
PSSRU (2016) Band 
8a - Page 137 
Banding as advised by 
Study Team 
Intervention cost 
Physiotherapist 
(Band 7) 0.8 
FTE 
£52 
12 Hours 
per week 
£17,472 
PSSRU (2016) Band 
7 - Page 137 
Banding as advised by 
Study Team 
Nurse (Band 7) 
0.8 FTE 
£52 
12 Hours 
per week 
£17,472 
PSSRU (2016) Band 
7 - Page 137 
Banding as advised by 
Study Team 
Overall cost of OGEP 
Intervention 
£35,812     
Cost of OGEP Intervention per 
participant 
£358.12 
Based on 100 
participants 
  
 
Resource use 
At baseline, there was considerable health care input over the 3 months recall period prior to 
receiving the OGEP; with district nurse visits showing the highest frequency of resource inputs 
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- mean number of visits per patient  45.6 (SD 37.6). When the median and range is examined, 
this also further illustrated the wide variation with median visits per patient at baseline 36 
(range 2-184).  At 3 months, these remained as the highest frequency of resource inputs -
mean number of visits per patient 21.8 (SD 21.7), and 20 (0-90) at 3 months In terms of biggest 
impact (either increase or decrease in resource use); district nurse visits, number of episodes 
of cellulitis, visits to see a specialist nurse about vascular problems; number of GP 
consultations (face-face and telephone) appear to show the most significant decrease in the 
after period. Again, examination of the median and range of visits showed a similar picture 
and illustrated the wide variation across patients in terms of resource consumption and 
associated costs.  
 
With regard to carer costs; there was an observed numerical reduction in paid carer visits at 
3 months compared to baseline (mean number of visits per patient at baseline 81 (SD 130.8) 
versus 73 (SD 123.1) visits per patient at baseline; however there were no observable 
differences when the median resource use is examined.  There was no difference in number 
of patients who were receiving the OGEP intervention as a full-time resident in either a 
residential or nursing care home at baseline and 3 months. 
 
 
Table 2: Summary of direct NHS/PSS health care costs 
  
Baseline 
  
3 Month Follow Up 
  
 
Time 
Point 
n Sum Mean 
(SD) 
Time Point n Sum Mean 
(SD) 
Difference if 
means (95% 
Confidence 
Interval) 
Total 
Costs 
Baseline 
(including 
PSS costs 
97 £563,729 
£5812 
(£5870) 
Total Costs 
3 Months 
(Including 
Intervention 
Costs) 
97 £445,098 
£4589 
(£5465) 
-£1222.9 (-
£344.5, -
£2101.5) 
Total 
baseline 
health 
care costs 
(excluding 
PSS costs) 
97 £282,539 £2912.77 
Total health 
care Costs 3 
Months 
(Including 
Intervention 
Costs) 
97 £173,385 £1787 
-£1,125.77 
(-£1,987, -
£264)  
 
The biggest differences at baseline and follow up are seen in district nurse home visits (mean 
patient cost £1207.8; SD £976.9) vs. £565.8 (SD £563.3); a difference of -£641.9; 95% CI (-
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£478.5; -£805.4) at follow up. Other cost differences were seen in GP face-face and telephone 
visits, costs associated with length of hospital stay and hospital admissions for cellulitis. When 
costs of dressing are examined there is a difference of £337.7 (95% CI £154, £521.13) between 
before and after. As would be expected, there were numerical differences seen when 
comparing the mean and median costs; but overall the pattern of observed differences was 
similar. 
This indicates that health care costs are reduced, in key categories such as district nurse visits 
and dressing costs, reduction in length of hospital stay by an average of 47%, and 38% 
respectively when examined in the before and after comparison of the OGEP. Whilst the 
analysis provides no indication of whether such costs are as a direct result of OGEP (as no 
randomised comparator) or whether these costs differences are sustained or change over 
time; this snapshot provides a tentative indication where the potential for OGEP to  be made 
in resource use and associated costs.  
The costs were estimated, with a NHS perspective only (i.e. direct health care costs to NHS 
Wales) and Personal Social Services (PSS) presented alongside. Overall, the total costs were 
£563,729 at baseline and £445,098 (including the addition of intervention costs) at follow up; 
indicating a cost difference (reduction) of £118,631 in 97 patients. When a cost per patient 
was examined, this equated to a mean difference (cost reduction) of £1222.9 (95%CI -£344.5, 
-£2101.5) between follow up and baseline assessments. A similar numerical difference was 
seen when direct health care costs were examined separately. However, the confidence 
intervals are very wide thus caution should be applied in extrapolating these results to any 
definitive claim of ‘cost saving or reduction’.  
Patient HRQOL outcome 
The results (Table 3) show the mean EQ-5D-5L utility score increased from 0.401 (SD 0.254) 
to 0.537 (SD 0.231) after the three month follow up.  This was a mean difference of 0.136 
(95% CI -0.098-0.174) which was statistically significant with p value of >0.001. When looking 
at the individual domains of the EQ-5D-5L, 43 participants (44%) increased their Mobility 
Score; 39 participants (40%) increased their Self Care Score; 29 participants (30%) increased 
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their Usual Activities Score; 47 participants 48 increased their Pain/Discomfort Score; and 28 
participants out of the 29 increased their Anxiety/Depression Score. 
 
Further, 49 participants (51% saw no change in their Mobility Score; 53 participants (55%) saw 
no change in their Self Care Score; 61 participants (63%) saw no change in their Usual 
Activities Score; 49 participants (51%) saw no change in their Pain/Discomfort Score; and 64 
participants (66%) saw no change in their Anxiety/Depression Score.    
        
Finally, 5 participants (5%) decreased in their Mobility Score; 5 participants (5%) decreased in 
their Self Care Score; 7 participants (7%) decreased in their Usual Activities Score; 1 
participant (1%) decreased in their Pain/Discomfort Score; and 5 participants (5%) 
decreased in their Anxiety/Depression Score.   
Table 3: Patient HRQOL outcome at baseline and 3 months  
 
  
n Mean SD 
95% Confidence 
Interval of the 
Difference 
p-value 
EQ-5D 5L 
Utility 
Baseline 
97 0.401 0.254 
-0.136 (-0.098, -0.174) <0.0001 
EQ-5D 5L 
Utility 
3Months 
97 0.537 0.231 
  
n Mean SD 95% Confidence 
Interval of the 
Difference 
p-value 
EQ-5D 5L VAS 
Baseline 
97 47.07 15.17 
14.69 (10.75, 18.63) <0.0001 EQ-5D 5L 
VAS 
3Months 
97 61.76 18.41 
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The results of the Visual Analogue Scale (VAS) show an increase from 47.07 (SD 15.17) to 
61.76 (SD 18.41) after the three month follow up. The mean difference of 14.69 (CIs 10.75, 
18.63) was also shown to be statistically significant (p-value >0.001). 
 
 
 
 
Summary 
Overall, the results from the pilot intervention suggests an observed picture within a short-
term horizon of an overall cost reduction when direct health care and PSS costs are 
considered; with suggestion that resources (and associated costs) are shifted from key areas 
such as district nursing and dressings. Whilst the small numbers in secondary care resource 
and costs are limited; there may be areas where observed trends in cost reductions warrant 
further exploration.  A small improvement in HRQOL score was observed in patients at 3 
months compared to baseline.  
 
Discussion 
The analysis reported as part of the pilot evaluation has provided a first in-depth examination 
on the impact that the OGEP model could make in developing and rolling out best ‘standard 
of care’ practice in delivering chronic oedema management including promotion of daily 
exercises within the community. This evidence at grass roots level can provide, from the 
outset, important preliminary evidence as to where the OGEP could make differences to the 
management of chronic oedema within NHS Wales.  Whilst from a decision makers’ 
perspective this is often ‘all about the evidence’; the pilot evaluation as a whole demonstrates 
that evidence should relate to the local health economy, patient health outcomes and 
experiences including the staff who are also beneficiaries of the OGEP through up-skilling 
their skills and competencies in delivering best standard care to this patient population.  As 
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such the evidence should be interpreted not just on the more general ‘reduction in costs to 
NHS Wales’. 
The findings show some interesting changes when resource use, costs and patient health 
outcomes are examined at baseline and 3 months follow-up with some differences shown in 
what would be potentially considered important and meaningful cost drivers in the 
management of chronic oedema such as reducing district nurse costs and dressing costs.  The 
pilot evaluation gives some indication of small patient HRQOL gains seen at follow up 
compared to baseline.  The presentation of these discrete categories allows the OGEP team 
to carefully scrutinise the results in order to a) see where the potential for most impact in 
reducing costs can be achieved and b) how there might be potential to  observe longer-term  
trends to show shifts in resources and potential for cost-reductions/savings. Further 
consideration of these results in terms of the potential in terms of how OGEP could optimise 
service capacity is important for the OGEP team when discussing next steps.  
Evidence of understanding where the potential cost drivers could be and whether health gains 
can be measured using instruments such as the EQ-5D 5L are fundamental components of 
pilot/feasibility work. A further, subsidiary research question from the analysis which may 
help future evaluations is formal examination of the   validity, reliability and sensitivity of the 
EQ-5D 5L within this patient population. Whilst this was outside the scope of this current pilot 
evaluation period, further analysis of the data collected could yield important insights into 
the psychometric and clinical utility of using this preference-based generic health measure in 
patients with chronic oedema.  
Limitations 
From the outset, we have been mindful that some of the methodological and practical 
constraints have impacted on the strength of the evidence delivered by this evaluation.  There 
is often a challenge in designing and conducting robust, ‘academically grounded’ evaluations 
when there is a compelling case for service innovation to respond quickly to meet unmet 
patient needs. Thus, the limitations often have to be set within context on what could be 
optimally achieved within real world settings.  
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Conclusion 
The economic analysis has provided a first in-depth examination on the economic and patient 
impact that the OGEP could make in providing an innovative solution to delivering best 
standard of care practice.  Whilst our findings suggest an observed trend for reductions in 
cost to NHS Wales; when disaggregated resource use and costs are examined, it also shows 
the possibility for a possible shift of health care resources across key areas of primary care 
and secondary care. The promotion of proactive care proves beneficial over reactive care. 
Further examination is required to assess whether these translate into potential efficiency 
gains (and important patient HRQOL gains) over the longer term. These findings can be used 
to inform the direction of any further development and evaluation of the OGEP model of care 
across NHS Wales.  
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